Drug Trial Radar · NCT02171910
Doxapram as an Additive to Propofol Sedation in Sedation for ERCP
Last checked: Nov 20, 2026Latest source record: Dec 5, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Oct 2016
Primary completion
Dec 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- Helsinki University Central HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Sedation is needed in order to complete endoscopic retrograde cholangiopancreatography (ERCP) to alleviate discomfort and pain during the procedure. This is usually achieved with use of opioids and/or sedative agents such as benzodiazepines or propofol. Traditionally benzodiazepines have been used but nowadays propofol is becoming the drug of choice for sedation during ERCP. The problem with propofol sedation is the fact that it may case cardiorespiratory depression and there is no antidote for this like there is for benzodiazepines. Cardiovascular depression can usually be easily counteracted with drugs that are used to raise blood pressure or heart rate during general anesthesia but respiratory depression remains a problem. The aim of this study is to try to counteract the respiratory depression caused by propofol sedation using an old respiratory stimulant doxapram as opposed to placebo using a double blind randomized protocol. The investigators hypothesis is that boluses and an infusion of doxapram will alleviate the respiratory depression caused by propofol sedation.
Conditions
- Sedation
- Hypoxia
Interventions
DoxapramDrug
PlaceboDrug
An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in arterial oxygenationTime frame: values recorded before the procedure, during the procedure at 5 min intervals and at the end of the procedure, on arrival at the recovery room and at 5 min, 10 min, and after that at 10 min intervals until discharge to ward
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Helsinki University Central Hospital
Helsinki, Uusimaa, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.